StreetAlpha
13F holdings · Q3 2026

Casdin Capital

New York, NY · files as Casdin Capital, LLC
Know the moment Casdin Capital filesYou follow Casdin Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1534261

Casdin Capital reported 48 stocks worth $2.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (23.0%), RLAY (12.6%) and WGS (11.7%). Compared with Q2 2026, the fund opened new positions in TEM, ORIC and BIIB, added to GRAL, NGNE and SRRK, trimmed PSNL, GPCR and DNLI and sold out of SION and IRON.

Latest filing: what Casdin Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
7 new8 added5 trimmed2 sold outBought about $180M · sold about $54.6M
New 7
See all 7 →
Added 8
See all 8 →
Trimmed 5
  • DNLI−$16.4M−39%
  • Biolife Solutions −$6M−3%
  • GPCR−$4.5M−12%
  • PSNL−$4.1M−10%
  • GLUE−$1.2M−54%
Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$2.3B+14.9% vs last quarter
Stocks held487 new · 2 sold out
Top 5 weight61.3%very concentrated
Turnover10%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RVMD
Revolution Medicines Inc
$529M23.0%2.6MNo change8 of 8
2
RLAY
Relay Therapeutics Inc
$289M12.6%16MNo change8 of 8
3
WGS
Genedx Holdings Corp
$268M11.7%3.7MNo change8 of 8
4
BIOLIFE SOLUTIONS INC
$175M7.6%4.5M−155K (−3%)8 of 8
5
ILMN
Illumina Inc
$145M6.3%530KNo change8 of 8
6
GRAL
Grail Inc
$95.3M4.2%680K+200K (+42%)3 of 8
7
TXG
10X Genomics Inc
$94.9M4.1%1.1MNo change4 of 8
8
LAB
Standard Biotools Inc
$65.8M2.9%88.8MNo change8 of 8
9
NGNE
Neurogene Inc
$44.1M1.9%1.6M+40K (+3%)8 of 8
10
SRRK
Scholar Rock Hldg Corp
$41.1M1.8%850K+185K (+28%)4 of 8
🔒 38 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
SION
Sionna Therapeutics Inc
$17.6M400K
IRON
Disc Medicine Inc
$4.8M65K

Reported value

last 8 quarters
$1.5BQ4 '24
$1.2BQ1 '25
$1.1BQ2 '25
$1.2BQ3 '25
$1.6BQ4 '25
$1.3BQ1 '26
$2BQ2 '26
$2.3BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Casdin Capital 13F FAQ

What does Casdin Capital own?

Casdin Capital reported 48 stocks worth $2.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (23.0%), RLAY (12.6%) and WGS (11.7%). The table above lists every position in the filing (the top 10 without an account).

What did Casdin Capital buy and sell in Q3 2026?

Compared with Q2 2026: 7 new positions, 8 added to, 5 trimmed and 2 sold out. New positions include TEM, ORIC and BIIB. It sold all of SION and IRON.

When will Casdin Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Casdin Capital's portfolio worth?

The Q3 2026 filing reports $2.3B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.